Bevital
Targeted metabolomics and Olink proteomics analysis services for researchers in nutrition, cardiovascular and cancer studies
Highlights
- New on EvolcAdded 2026-10-28
About Bevital
Bevital AS provides targeted metabolomics analyses using isotope-labelled internal standards, organised into pre-designed panels for cardiometabolic, inflammation and immune activation, microbiome, and nutrition and lifestyle markers. Customised panels can be assembled from its marker portfolio. The company also offers Olink proteomics panels and multiomics data analysis in partnership with Biogenity.
Its customers are research groups and scientists in nutrition, cardiovascular disease, cancer and neurodegenerative research, and it also provides academic support such as funding application writing and statistical analysis. The website describes Bevital as a non-profit organisation.
Bevital was founded in 2003 and is registered in Bergen, Norway, with its address at Minde Allé 35 in Bergen. The team lists research, laboratory and advisory roles, and its scientific advisor Per Magne Ueland is a former professor at the University of Bergen.
Product: Targeted metabolomics analysis panels, Olink proteomics panels and multiomics data analysis services for research.
Jobs at Bevital
Leadership
- Randi Mjelde Heimdal · Manager, MScSource: company website
More biotech & pharma companies
Bio-Me
QPCR-based microbiome profiling for researchers, pharma and consumer health companies, with diagnostic test developmentNew on EvolcBio-Rad Norway
Life science research and clinical diagnostic products for researchers, laboratories and healthcare providersNew on EvolcBiobank
Biobanking and genetic testing services for animal breeders and breeding organisationsNew on EvolcBionér
Soil and compost analysis services for farmers, compost producers and other land usersNew on EvolcBlue Analytics
Diagnostic and genomic lab analyses for fish health and aquaculture producers, run in Bergen, NorwayNew on EvolcCalluna Pharma
Clinical-stage biotech developing antibodies against fibrosis and inflammation, with lead asset CAL101 for IPFYoung companyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- CookieYes
- Elementor
- Google Tag Manager
- Google reCAPTCHA
- LinkedIn Insight
- PHP
- WordPress
- jQuery
